Covance
A Leading Provider Of Bioanalytical Laboratory Solutions And Services

Over the years, biopharma companies have been racing to discover effective treatments and vaccines for novel conditions and diseases. Today, the COVID-19 pandemic has not only created newer opportunities for these companies to demonstrate their industry’s value, but it also has led to potential short- and long-term challenges. Suspended trials, delayed product launches, the inability of the sales force to carry out in-person visits, supply chain disruption, and overall delays in drug commercialization have been the direct effects of the pandemic. In addition, global economic volatility, uncertainty regarding trade and supply chain regulation, and sourcing is increasingly calling on leaders to develop, implement, and sustain new initiatives. “Together with its clients, Covance helps support the development of innovative, life-changing treatments,”- Cheerag Shirodaria, VP and GM of Covance. A leading global life sciences company by Labcorp, Covance provides contract research services to the drug, medical device and diagnostics, crop protection, and chemical industries. The company employs over 26,000 people worldwide on a mission to advance health and power clear, confident decisions with its comprehensive drug development solutions.

A global leader in clinical trial testing, non-clinical safety assessment, and clinical trial management services, Covance’s unique perspectives are based on decades of scientific, medical, and regulatory expertise. Through its state-of-the-art diagnostics and drug research development capabilities, the company provides insights and accelerates innovations to improve healthcare. From preclinical testing and clinical trials to post-market monitoring, Covance helps biopharma organizations advance with a holistic development plan propelled by a strategic and regulatory-driven approach. The company partners to help clients determine the

best strategy for their drug candidate and implement a solution that delivers the most value from the program. Its experts will work collaboratively to meet project needs, leveraging experience from developing more than 1,000 methods annually and supporting more than 260 unique compounds annually.

Covance ensures clients keep their timeline on track with scientific expertise, operational experience, and up-to-date knowledge of the regulatory environment. The company ensures specimen safety and integrity in its purpose-built biorepository backed by fully redundant power supplies and auditable tracking systems throughout the chain of custody. By seamlessly combining codified informed consent with the specimen, clinical and biomarker data—Covance uses its ‘GlobalCODE specimen lifecycle management service’ to further accelerate drug development programs. Users can view sample reconciliation and codified consent management to proactively address risks by managing patient enrollment and implementing risk-based monitoring strategies. Furthermore, the company uses the best-in-class customized, bar-coded, visit-specific specimen collection kits and relies on its globally-located team of more than 50 logistics experts for contingency plans that help assure on-time and in-stability shipments. Clients can view individual test results, monitor trends, track sample shipments, confirm site communications, order kits, and access version-controlled laboratory manuals all through its ‘Xcellerate Lab portals,.’ In the future, Covance aims to continue creating new tailored approaches that will enable biopharma companies to bring their products to the market faster and optimize the device development process. “As the lines continue to blur between drug, device, and diagnostic testing, our company sits at a unique intersection to bring you transformational insights and solutions,” - Cheerag Shirodaria